Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 766010714 | 7660107 | 14 | F | 201302 | 20130926 | 20101108 | 20130930 | EXP | PHHY2010CA65351 | NOVARTIS | 60.70 | YR | F | Y | 0.00000 | 20130930 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 766010714 | 7660107 | 1 | PS | SANDOSTATIN LAR | 1 | INTRAMUSCULAR | 40 MG, (EVERY 4 WEEKS) | U | 21008 | 40 | MG | SUSPENSION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 766010714 | 7660107 | 1 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 766010714 | 7660107 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 766010714 | 7660107 | Blood pressure increased | |
| 766010714 | 7660107 | Injection site haemorrhage | |
| 766010714 | 7660107 | Local swelling | |
| 766010714 | 7660107 | Musculoskeletal pain | |
| 766010714 | 7660107 | Pain | |
| 766010714 | 7660107 | Skin injury | |
| 766010714 | 7660107 | Thrombosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 766010714 | 7660107 | 1 | 20090515 | 0 |